ATX

Amplia Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

Amplia Therapeutics Limited focuses on developing therapies targeting focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company is positioned within the biotechnology sector, leveraging advanced scientific research to develop clinical candidates aimed at unmet medical needs, potentially offering transformative therapies in oncology and fibrotic diseases.

focal adhesion kinase

cancer treatment

drug development

biotechnology

Shorted

short percentage0.07%

reported shorts375.2K

shares on issue513.072M

About

website

ampliatx.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Level 17, 350 Queen Street, MELBOURNE, VIC, AUSTRALIA, 3000

Connect

Key Metrics

market cap

$66.70M

price$0.13

eps$-0.02

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

focal adhesion kinase

cancer treatment

drug development

biotechnology

pharmaceuticals

Company Overview

AI-generated company summary

Company History

Amplia Therapeutics Limited, previously known as Innate Immunotherapeutics, was founded with a focus on developing treatments for serious diseases. The company pivoted towards its current focus on FAK inhibitors around 2018 following a strategic acquisition of intellectual property. Amplia listed on the ASX and has successfully advanced its lead FAK inhibitor, AMP945, into clinical trials, marking a significant milestone in its operational history.

Competitive Advantages

Amplia holds proprietary technology in FAK inhibition, offering potential first-in-class treatments for specific cancer and fibrosis indications. The company benefits from strong scientific foundations and strategic intellectual property, positioning it favorably within the biotechnology space.

Risk Factors

•Clinical trial uncertainties and potential failures
•Regulatory approval challenges for new drug candidates
•Dependence on securing additional funding for ongoing development

Recent Developments

Last 6 months

In the past six months, Amplia has made significant progress with its lead candidate, AMP945, commencing a Phase 2 clinical trial for pancreatic cancer treatment. The company reported encouraging interim results in the preclinical studies of AMP945, further bolstering their development pipeline.

Key People

Leadership team at Amplia Therapeutics

John Lambert

CEO

John Lambert brings over 20 years of leadership experience in the biotechnology sector, having previously held senior positions in both public and private life sciences companies. He oversees Amplia's strategic direction and clinical development programs.

Mark Devlin

CFO

Mark Devlin is an experienced finance professional with a background in financial management within the pharmaceutical and biotechnology industries. He manages Amplia's financial operations and investor relations strategies.